Anti-Cancer Properties of the Naturally Occurring Aphrodisiacs: Icariin and Its Derivatives by Hui-Li Tan et al.
REVIEW
published: 29 June 2016
doi: 10.3389/fphar.2016.00191
Frontiers in Pharmacology | www.frontiersin.org 1 June 2016 | Volume 7 | Article 191
Edited by:
Lyndy Joy McGaw,
University of Pretoria, South Africa
Reviewed by:
Fang-Rong Chang,
Kaohsiung Medical University, Taiwan
Amit Kumar Tyagi,
The University of Texas MD Anderson
Cancer Center, USA
*Correspondence:
Learn-Han Lee
lee.learn.han@monash.edu;
Bey-Hing Goh
goh.bey.hing@monash.edu
Specialty section:
This article was submitted to
Ethnopharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 01 March 2016
Accepted: 16 June 2016
Published: 29 June 2016
Citation:
Tan H-L, Chan K-G, Pusparajah P,
Saokaew S, Duangjai A, Lee L-H and
Goh B-H (2016) Anti-Cancer
Properties of the Naturally Occurring
Aphrodisiacs: Icariin and Its
Derivatives. Front. Pharmacol. 7:191.
doi: 10.3389/fphar.2016.00191
Anti-Cancer Properties of the
Naturally Occurring Aphrodisiacs:
Icariin and Its Derivatives
Hui-Li Tan 1, 2, Kok-Gan Chan 3, Priyia Pusparajah 2, Surasak Saokaew 1, 4, 5,
Acharaporn Duangjai 4, 6, Learn-Han Lee 1, 4* and Bey-Hing Goh 1, 4*
1Novel Bacteria and Drug Discovery Research Group, School of Pharmacy, Monash University Malaysia, Bandar Sunway,
Malaysia, 2 Biomedical Research Laboratory, Jeffrey Cheah School of Medicine and Health Sciences, Monash University
Malaysia, Bandar Sunway, Malaysia, 3Division of Genetic and Molecular Biology, Faculty of Science, Institute of Biological
Sciences, University of Malaya, Kuala Lumpur, Malaysia, 4Center of Health Outcomes Research and Therapeutic Safety
(Cohorts), School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand, 5 Pharmaceutical Outcomes
Research Center, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand, 6Division of Physiology,
School of Medical Sciences, University of Phayao, Phayao, Thailand
Epimedium (family Berberidaceae), commonly known as Horny Goat Weed or Yin
Yang Huo, is commonly used as a tonic, aphrodisiac, anti-rheumatic and anti-cancer
agent in traditional herbal formulations in Asian countries such as China, Japan, and
Korea. The major bioactive compounds present within this plant include icariin, icaritin
and icariside II. Although it is best known for its aphrodisiac properties, scientific
and pharmacological studies suggest it possesses broad therapeutic capabilities,
especially for enhancing reproductive function and osteoprotective, neuroprotective,
cardioprotective, anti-inflammatory and immunoprotective effects. In recent years, there
has been great interest in scientific investigation of the purported anti-cancer properties
of icariin and its derivatives. Data from in vitro and in vivo studies suggests these
compounds demonstrate anti-cancer activity against a wide range of cancer cells
which occurs through various mechanisms such as apoptosis, cell cycle modulation,
anti-angiogenesis, anti-metastasis and immunomodulation. Of note, they are efficient at
targeting cancer stem cells and drug-resistant cancer cells. These are highly desirable
properties to be emulated in the development of novel anti-cancer drugs in combatting
the emergence of drug resistance and overcoming the limited efficacy of current standard
treatment. This review aims to summarize the anti-cancer mechanisms of icariin and its
derivatives with reference to the published literature. The currently utilized applications
of icariin and its derivatives in cancer treatment are explored with reference to existing
patents. Based on the data compiled, icariin and its derivatives are shown to be
compounds with tremendous potential for the development of new anti-cancer drugs.
Keywords: icariin, icaritin, icariside II, Yin Yang Huo, anti-cancer, ethnopharmacology
INTRODUCTION
Cancer is a growing health problem, representing one of the leading causes of mortality worldwide
(Goh and Kadir, 2011). The current standard of care includes conventional medicine, surgery,
radiotherapy, and chemotherapy (Hsiao and Liu, 2010) however the limitations of existing care are
clear as even after completion of the standard treatment regimens, there are high rates of metastasis
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and relapse (Liang et al., 2010). In addition, there are significant
problems associated with the standard treatments such as
significant toxicity levels and the emergence of resistance toward
anti-cancer drugs, making treatment of cancer even more
challenging (Crespo-Ortiz and Wei, 2012). Consequently, the
annual death rates due to cancer cannot be significantly lowered
(Chan et al., 2015) unless new treatment strategies can be devised.
Scientific exploration of medicinal plants and herbs is now
of increasing interest in the hope that they will yield novel
compounds with properties that can overcome the limitations
of the drugs currently available (Lau et al., 2015; Supriady et al.,
2015). Plant based compounds are also of interest due to their
multitargeting properties, low cost, relative absence of toxicity
and high availability (Gupta et al., 2011; Tan et al., 2015; Sayyad
et al., in press).
Epimedium (family Berberidaceae), (Latin name Herba
Epimedii) commonly known as Horny Goat Weed or Yin Yang
Huo in Chinese, is a genus consisting of approximately 52 species
of herbaceous flowering plants (Ma et al., 2011). In recent years,
there has been a significant volume of research on the anti-cancer
effect of the main active compounds from Herba Epimedii such
as icariin, icaritin, and icariside II. Icariin and its derivatives,
icaritin, and icariside II seem to be promising compounds for
cancer treatment, with studies having shown that they exhibit
anti-cancer activity against a wide range of cancer cell types
such as osteosarcoma (Geng et al., 2014), prostate (Lee et al.,
2009), lung (Zheng et al., 2014), gastric (Wang et al., 2010),
and kidney cancer cells (Li et al., 2013b). These compounds
exert their anticancer action via a multitude of cellular targets
and through a variety of pathways including apoptosis inducing
effect, cell-cycle modulation, anti-angiogenesis, anti-metastasis,
and immunomodulation. Of particular interest, they effectively
target cancer stem cells and drug resistant cancer cells. Research
also suggests they are able to potentiate the current standard
cancer treatments. The purpose of this review is to provide
an up-to-date of the anti-cancer mechanisms of icariin and its
derivatives; and to provide scientific evidence that there is a basis
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to support the efficacy ofHerba Epimedii-based traditional herbal
formulations for the treatment of cancer. Overall, the existing
literature highlights the remarkable potential of these compounds
for the development of novel drugs for cancer treatment.
PLANT DESCRIPTION AND TRADITIONAL
USES
Epimedium is a low-growing, deciduous plant with leathery
leaves that spreads by underground stems. The flowers of
Epimedium vary in color and they have eight sepals. A tough
and long-lived perennial species, Epimedium is found mainly on
cliffs in moist forests, near streams and wet lands at altitudes of
between 200 and 3700m (Ma et al., 2011). Epimedium is widely
distributed from Japan to Algeria but it is mostly found in the
East Asian and Mediterranean region (Arief et al., 2015).
Epimedium species have a long history of use in traditional
medicine as they have been used in botanical supplements for
more than 2000 years. The extracts of Epimedium plants are
included in traditional herbal formulations for the treatment of
infertility, rheumatism and cancer in Asian countries such as
China, Japan, and Korea. In China, Epimedium is taken as a
supplement for prevention of chronic diseases and to strengthen
the body (Cassileth et al., 2010; Ma et al., 2011). Today, Herba
Epimedii is still popular in the treatment of cancers; it has
been commonly used as one of the main ingredients together
with other herbs, for the preparation of traditional Chinese
formulations to treat various cancers such as digestive system
cancers, hepatocarcinomas, lung cancers, breast cancers and
cervical cancers (Zhang, 1991; Qi and Qi, 2002; Wang, 2003;
Teng, 2010). With reference to formal research, the extracts of
Herba Epimedii were reported to display anti-cancer activity
in cancer cell lines such as colon cancer cells, hepatoma and
leukemia cells (Lin et al., 1999; Guon and Chung, 2014). Given
the apparent efficacy of Herba Epimedii in treating cancers,
phytochemical analyses have also been carried out to identify
the bioactive components responsible for its pharmacological
activities.
ICARIIN AND ITS DERIVATIVES
More than 260 moieties can be detected in Herba Epimedii,
including flavonoids, lignins, ionones, phenol glycosides,
phenylethanoid glycosides, sesquiterpenes, and other types of
compounds (Ma et al., 2011). Among the compounds identified,
icariin is thought to be the principal bioactive compound in
Epimedium extracts. Aside from icariin, derivatives such as
icaritin, icariside I, icariside II, and desmethylicaritin can also
be found in Herba Epimedii (Ma et al., 2011). Metabolic and
pharmacokinetic studies have shown that these derivatives can
also be obtained through the metabolism of icariin by intestinal
flora, by converting icariin to icaritin, icariside I, icariside II, and
desmethylicaritin (Liu et al., 2005; Xu et al., 2007). As shown
in Figure 1, icariin (1) is a prenylated flavonol glycoside with
rhamnosyl, glucosyl, and methoxy groups. Deglycosylation or
demethylation of icariin will form different metabolites. For
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FIGURE 1 | Chemical structures of icariin and its derivatives isolated from Herba Epimedii. Icariin (1), icaritin (2), and icariside II (3).
instance, icariside I will be formed when the rhamnose residue
is removed whereas icariside II (3) will be formed when the
glucose residue is removed. Deglycosylation of icariin will
result in icaritin (2) and demethylation of icaritin will result in
desmethylicaritin (Shen et al., 2009; Khan et al., 2015).
Scientific studies have provided evidence of the broad
therapeutic capabilities of icariin, especially with reference
to its effects on reproductive function (Chen et al., 2014),
osteoprotective (Qin et al., 2008), neuroprotective (Nie et al.,
2010), cardioprotective (Ding et al., 2007), anti-inflammatory
(Xu et al., 2010), and immunoprotective effects (Li et al., 2011).
Icariin’s derivatives have also been shown to possess significant
biological activities. For example, icaritin was shown to possess
osteopromotive (Yao et al., 2012), neuroprotective (Wang et al.,
2007) and cardioprotective effect (Lei et al., 2015). The number
of studies on icariside I are limited but it was reported to alleviate
sexual dysfunction (Lenoble et al., 2002). Icariside II, is reported
to possess anti-hepatotoxic (Cho et al., 1995), anti-osteoporosis
effects (Liu et al., 2014) and the ability to ameliorate diabetic
neuropathy (Tian et al., 2015). Icariin, icaritin and icariside II,
have also been reported to possess anticancer activity. Results
of both in vitro and in vivo experiments have suggested these
compounds hold promise for cancer treatment because they
are effective against a wide range of cancer cell types including
osteosarcoma (Geng et al., 2014), prostate (Lee et al., 2009),
lung (Zheng et al., 2014), gastric (Wang et al., 2010), kidney
(Li et al., 2013b). Furthermore, these compounds seem to exert
their anticancer actions through different cellular targets and
pathways. It is crucial to attain a more complete understanding
of the underlying mechanisms of the anticancer properties of
icariin and its derivatives to provide direction for future research
in cancer drug discovery.
ANTICANCER PROPERTIES
Apoptotic Activity
Over the past decade, triggering apoptosis in tumor cells has been
utilized as an effective approach for treatment of cancer (Han
et al., 2015). Apoptosis occurs through two different pathways:
the extrinsic or death receptor pathway and the intrinsic or
mitochondrial pathway (Goh et al., 2014). Both pathways of
apoptosis involve the activation of initiator caspases, followed
by activation of effector caspases (caspase-3, -6, and -7) which
the major executioners of apoptosis (Mongiat et al., 2007;
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Ahmed and Othman, 2013). With reference to the intrinsic
pathway, mitochondrial outer membrane permeabilization is the
crucial event for initiator caspase activation (Chan et al., 2012).
Herba Epimedii was shown to induce apoptosis of cancer cells;
70% ethyl alcohol extracts of Epimedium koreanum Nakai has
caused activation of mitochondria-dependent apoptotic pathway
in colon cancer cells (Guon and Chung, 2014). This led to
further studies on the apoptotic activity induced by the bioactive
components isolated from this herb. Generally, the apoptotic
effect of icariin and its derivatives has been associated with
the activation of the intrinsic pathway of apoptosis. Treatment
with icariin and icaritin has resulted in increase in Bax/Bcl2
ratio, release of cytochrome c, cleavage of poly (ADP-ribose)
polymerase and activation of caspases in a wide range of
cancer cells (He et al., 2010; Li et al., 2010, 2013a, 2014b;
Tong et al., 2011; Wang et al., 2011a; Zhu et al., 2011; Sun
et al., 2015b; Wu et al., 2015b); these can be regulated by
various signaling pathways, as shown in Table 1. Similarly,
icariside II has been shown to increase the ratio of Bax/Bcl2,
causing transposition of cytochrome c and activation of caspase-
3 and -9 in cancer cells including lung cancer cells and acute
myeloid leukemia cells. It also causes degradation of poly
ADP-ribose polymerase (PARP) and reactive oxygen species
(ROS) over-production (Kang et al., 2012; Song et al., 2012).
Additionally, apoptosis of esophageal squamous cell carcinoma
treated with icariside II has been reported to be associated
with lowered expression of β-catenin and downregulation of
expression of survivin and cyclin D1, suggesting that icariside
II is capable of simultaneously inducing apoptosis while also
inhibiting proliferation of cancer cells (Wang et al., 2011b).
Other mechanisms involved include inhibition of epidermal
growth factor receptor (EGFR) pathway activation (Wu et al.,
2013b) which then prevents the downstream activation of the
JAK/STAT3 pathway (Kim et al., 2011; Wu et al., 2013a). This
shows the ability of icariside II to overcome the survival signals
of tumor cells because STAT3 is one of the STAT proteins that
is constitutively active in cancer cells where it promotes the
expression of antiapoptotic proteins (Wu et al., 2013a). Icariside
II also helps to overcome the survival signals of tumor cells by
inhibiting cyclooxygenase-2 (COX-2)/PGE2 pathway (Lee et al.,
2009); expression of COX-2 has been associated with tumor-cell
resistance to apoptosis (Greenhough et al., 2009).
The extrinsic pathway, on the other hand, is activated
by specific receptors of the tumor necrosis factor receptor
superfamily, such as Fas, DR4 (TRAIL-R1), and DR5 (TRAIL-
R2). The binding of their specific ligands will result in the
production of death-inducing signaling complex and activation
of caspase-8 and caspase-10 which will then activate the effector
caspases (Mongiat et al., 2007). In some studies, both intrinsic
and extrinsic pathways seem to be involved in the induction
of apoptosis by icariin and its derivatives. For example, the
treatment of human hepatocellular carcinoma with icaritin not
only triggered mitochondrial/caspase apoptotic pathway but
also induced apoptosis through Fas-mediated caspase-dependent
pathway as evidenced by increased levels of Fas and cleaved
caspase-8 (Sun et al., 2015b). Similar results were obtained in
breast cancer cells treated with Icariside II (Huang et al., 2012).
Aside from mitochondria, organelles such as endoplasmic
reticulum and lysosomes also play an important role in apoptosis
of cancer cells (Geng et al., 2015). The rapid rate of glucose
metabolism and growth in cancer cells causes endoplasmic
reticulum stress (ERS) and activation of the unfolded protein
response (UPR). As the UPR is one of the resistance mechanisms
against cancer therapy, it can often enable cancer cells to adapt to
ERS and evade apoptotic pathways (Yadav et al., 2014). However,
some studies have shown that therapeutic induction of ERS-
induced apoptosis can be useful in eradicating cancer cells if
there is forced activation of ERS (Di et al., 2015; Fan et al.,
2016). Recently, the role of ERS signaling in the anticancer
activity of icariin has been studied on human adenocarcinoma
and esophageal cancer cells. Icariin treatment upregulated ERS-
related molecules such as p-PERK, ATF, GRP78, p-eIF2α, CHOP
as well as apoptosis-related protein PUMA. At the same time,
there was downregulation of anti-apoptosis-related protein Bcl2.
This demonstrated that the apoptotic activity of icariin in cancer
cells might also be due to activation of ERS signaling (Di et al.,
2015; Fan et al., 2016).
Lysosomes are acidic organelles containing various hydrolytic
enzymes for recycling of intracellular proteins. When the
alteration in lysosomal membrane permeabilization occurred,
there will be release of its hydrolytic enzymes, leading to a
change in mitochondrial membrane potential and subsequent
pro-apoptotic events of cells (Geng et al., 2015). In a
recent study, it was shown that treatment with icariside
II induced both mitochondrial and lysosomal dysfunction
through mitochondrial membrane and lysosomal membrane
permeabilization in human hepatoblastoma cells, leading to
caspase activation and cell apoptosis (Geng et al., 2015). This
shows that icariside II is able to induce cancer cell apoptosis by
causing both mitochondrial and lysosomal damage.
Therefore, icariin and its derivatives appear to be effective in
inducing apoptosis in a wide range of cancer cell types through a
variety of cell signaling mechanisms (Figure 2).
Cell-Cycle Modulation
The cell cycle consists of phases known as G0, G1, S, and G2M.
Cyclin-dependent kinases (CDK) are the protein translating
signals that push the cells through the cell cycle and the growth of
cells is dependent on their capability to translate these signals for
effective replication and division. When the normal regulation
of cell-cycle progression and division is disrupted, uncontrolled
proliferation can occur which may result in the development of
cancer (Crespo-Ortiz and Wei, 2012; Dinicola et al., 2014).
Icariin and its derivatives inhibit the growth of cancer cells by
causing cell cycle arrest. Icariin induces cell cycle arrest at G0/G1
and G2/M phases in gallbladder carcinoma cells and colorectal
cancer cells respectively, through the inhibition of NF-κB activity
(Zhang et al., 2013, 2014). Icaritin inhibits growth of human
prostate carcinoma cells through G1 cell cycle arrest which is
attributed to induction of p27Kip1, p16Ink4a, and pRb, as well
as the down-regulation of expression of phosphorylated pRb,
cyclin D1 and CDK4 (Huang et al., 2007). In other work, icaritin
caused cell cycle arrest at the G2/M phase in extranodal NK/T-
cell lymphoma cells (Wu et al., 2015b). Similarly, treatment
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TABLE 1 | Apoptotic activity of icariin and its derivatives.
Compound Cell Line Study Type Mechanism References
Icariin Human lung adenocarcinoma cells (A459) In vitro and
In vivo
Activation of ERS signaling, increased expression of ERS-related
molecules (p-ERK, ATF6, GRP78, p-eIF2α, and CHOP,
downregulation of Bcl2 expression and upregulation of PUMA
Di et al., 2015
Human esophageal cancer cells (EC109 and
TE1)
In vitro and
In vivo
Activation of ERS signaling, increased expression of ERS-related
molecules (p-ERK, ATF4, GRP78, p-eIF2α, and CHOP,
downregulation of Bcl2 expression and upregulation of PUMA
Fan et al., 2016
Human hepatoma cells (SMMC-7721,
Bel-7402, and HepG2)
In vitro and
In vivo
Activation of ROS/JNK-dependent mitochondrial pathway that
involved the generation of ROS and JNK activation, resulted in
enhanced Bax-to-Bcl-2 ratio, loss of mitochondrial membrane
potential, cytochrome c release, and caspase cascade
Li et al., 2010
Mouse tumor Leydig cells (MLTC-1) In vitro Activation of caspase-9, -3, enhanced Bax/Bcl-2 ratio, and
release of cytochrome c, as well as down-regulation of the
expression of piwil4
Wang et al., 2011a
Icaritin Hepatocellular Carcinoma (HepG2) In vitro Enhanced Bax/Bcl-2 ratio, activation of caspase-3, activation of
JNK1 signaling
He et al., 2010
Leukemia cells (Primary acute myeloid
leukemia cells, NB4, HL60, and U937)
In vitro Activation of caspase-9, -3, -7, cleavage of PARP, downregulation
of c-myc, inhibition of MAPK/ERK, and PI3K/AKT signals.
Li et al., 2013a
Human Burkitt lymphoma cells (Raji and
P3HR-1)
In vitro Activation of caspase-8, -9, cleavage of PARP, downregulation of
c-myc and enhanced Bax/Bcl-2 ratio
Li et al., 2014b
Human liver cells (L02) and Human
hepatocarcinoma cells (SMMC-7721)
In vitro Activation of caspase-3, -8, enhanced Bax/Bcl-2 ratio, increased
expression levels of Fas
Sun et al., 2015b
Human endometrial cancer cells (Hec1A) In vitro Activation of caspase-3 and caspase-9, cleavage of PARP, release
of cytochrome c, enhanced Bax/Bcl-2 ratio, and sustained
activation ERK1/2 signaling
Tong et al., 2011
Extranodal NK/T-cell lymphoma cells (SNK-10
and SNT-8)
In vitro Activation of caspase-3 and caspase-9, enhanced Bax/Bcl-2 ratio,
downregulation of p-Bad, inhibition of Jak/Stat3, and PI3K/Akt
signaling pathway mediated by reduced expression of LMP1
Wu et al., 2015b
Leukemia cells (Primary chronic myeloid
leukemia cells and K562)
In vitro and
In vivo
Activation of caspase-3, -9, release of cytochrome c, enhanced
Bax/Bcl-2 ratio, downregulated expression of Apaf-1, inhibition of
MAPK/ERK/JNK signals and down-regulated kinase activity of
Jak-2/STAT3/Akt signal network
Zhu et al., 2011
Icariside II Human hepatoblastoma cells (HepG2), Mouse
liver carcinoma cells (H22)
In vitro and
In vivo
Mitochondrion membrane and lysomal membrane
permeabilization, activation of caspase-3, -7, -8, -9, cleavage of
PARP, enhanced Bax/Bcl-2 ratio.
Geng et al., 2015
Human breast cancer cells (MCF-7) In vitro Activation of caspase-8, -9, decreased mitochondrial potential,
release of cytochrome C and AIF, increased expression of Fas and
FADD as well as increased expression of Bax and BimL
Huang et al., 2012
Human acute myeloid leukemia cells (U937) In vitro Activation of caspase-3, cleavage of PARP, and decreased bcl-xL
and survivin, inactivation of STAT3-related signaling pathway.
Kang et al., 2012
Multiple myeloma cells (U266) In vitro Down-regulation of expression of Bcl-2, Bcl-xL, survivin, Cyclin
D1, COX-2, and VEGF, enhanced PARP cleavage and caspase-3
activation, inhibition of STAT3 activation and enhanced expression
of SHP-1 and PTEN through inhibiting JAK2 and c-Src
Kim et al., 2011
Human prostate cancer cells (PC-3) In vitro Activation of caspase-8, -9, -3, cleavage of PARP, decreased
mitochondrial potential, COX-2, iNOS, and VEGF expression,
release of cytochrome C, inhibition of COX-2/PGE2 pathway
Lee et al., 2009
Human non-small cell lung cancer cells (A549) In vitro Activation of caspase-3, -9, cleavage of PARP, release of
cytochrome c, enhanced Bax/Bcl-2 ratio, Activation of
ROS/MAPK pathway that involved activation of ROS downstream
effectors, JNK and p38MAPK
Song et al., 2012
Human eosophageal squamous carcinoma
(Eca109)
In vitro and
In vivo
Downregulation of survivin and Cyclin D1, inhibition of
β-catenin-dependent signaling.
Wang et al., 2011b
Human epidermoid carcinoma cells (A431) In vitro Activation of caspase-9, cleavage of PARP, inhibition of
JAK/STAT3 and MAPK-ERK pathways, activation of PI3K/AKT
pathway, inhibition of EGF-induced activation of EGFR pathway.
Wu et al., 2013b
Human melanoma cells (A375 and SK-MEL-5)
and Mouse melanoma cells (B16)
In vitro and
In vivo
Activation of caspase-3, decreased expression of survivin,
inhibition of JAK/STAT3 and MAPK pathways as well as activation
of PI3K/AKT pathway
Wu et al., 2013a
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FIGURE 2 | Icariin, icaritin, and icariside II exert apoptotic effects through multiple mechanisms, which include the inhibition of β-catenin-dependent
signaling, EGFR signaling, MAPK/ERK signaling, PI3K/Akt signaling, JAK/STAT3 signaling, and COX-2/PGE2 signaling. The activated pathways are such
as ROS/JNK dependent mitochondria pathway, FAS-dependent apoptosis, JNK1 signaling, ERS signaling and ERK1/2 signaling. PI3K/Akt signaling can also be
activated to inactivate JAK/STAT pathway.
of breast cancer cells with icaritin resulted in cell cycle arrest
at the G2/M phase, accompanied by down-regulation of the
expression of G2/M phase regulatory proteins including cyclin
B, cdc2 as well as cdc25c (Guo et al., 2011). The cell cycle
arrest was associated with sustained extracellular signal-regulated
kinases (ERK) activation, consistent with the findings of Tong
et al. (2011). Aside from these, icaritin has been shown to
induce cell cycle arrest in the S phase associated with down-
regulated expression levels of S regulatory proteins including
Cyclin A, Cyclin B, and CDK2 in lung cancer and chronic
myeloid leukemia cells (Zheng et al., 2014; Zhu et al., 2015). As
shown in Figure 3, the cell cycle modulation of icaritin seems
to vary from study to study and this might be due to the cell
type species-differences of the cancer cell lines (Zheng et al.,
2014). Icariside II also inhibits cancer cell proliferation through
cell cycle modulation (Wang et al., 2011b); it was able to induce
cell cycle arrest at G0/G1 and G2/M transitions. The underlying
mechanism was suggested to be due to the generation of reactive
oxygen species as well as activation of p38 and p53 (Wu et al.,
2015a). In a study on osteosarcoma, the inhibition of cancer
cell proliferation by icariside II was associated with its ability to
inactivate epidermal growth factor receptor (EGFR)/mammalian
target of rapamycin (mTOR) pathway, showing that icariside II
might target mTOR, the master switch of tumor cell proliferation
(Geng et al., 2014).
Based on these studies, icariin and its derivatives were
demonstrated to exert cell cycle modulation at different phases
resulting in an anti-proliferative effect on cancer cells; mainly
attributed to the downregulation of cell cycle regulatory proteins,
as summarized in Table 2.
Angiogenesis Inhibition
Angiogenesis is the vital physiological process of formation
of new blood vessels; it is a normal process in growth and
granulation tissue formation. Angiogenesis is crucial for cancer
development because blood vessels supply the nutrition and
transfer channels at every stage of the growth of tumor (Zhang,
2014). Therefore, disruption of angiogenesis can cause inhibition
of tumor invasion and metastasis (Tan et al., 2016). Currently,
anti-angiogenesis treatment represents one of the strategies
in cancer therapy but the currently known effective anti-
angiogenesis agents are prohibitively expensive.
The potential of Herba Epimedii to inhibit angiogenesis was
investigated in vitro and in vivo, as summarized in Table 3.
Anti-angiogenic effects of the ethyl acetate fraction of Herba
Epimedii extract was demonstrated in both experimental models
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FIGURE 3 | Cell cycle modulation by icariin and its derivatives. Icariin, icaritin, and icariside II induce cell cycle arrest through modulation of expression of cell
cycle regulatory proteins at different stages of cell cycle, resulted in inhibition of tumor growth.
and might be due to inhibition of ERK signaling pathway
(Yu et al., 2013). Preliminary studies on the effect of active
compounds of Herba Epimedii such as icariin and icaritin on
angiogenesis have been carried out by using human umbilical
vein endothelial cells as a cell model of angiogenesis. Both
icariin and icaritin were found to inhibit the proliferation,
migration as well as tube formation of the cells (Zhang, 2014;
Ye et al., 2015). In a chick embryo chorioallantoic assay, there
was significant reduction in newly-formed blood vessels as well as
reduced area and length of blood vessels that occurred in a dose-
dependent manner following treatment of icariin and icaritin
(Hong et al., 2013; Ye et al., 2015). Icariin and its derivatives have
also exhibited their anti-angiogenic activity in vivo in different
xenograft models of tumors such as hepatocellular carcinoma and
renal cell carcinoma. CD31 is a pan-endothelial marker which is
specifically expressed on the endothelial cells surfaces; in tumors
of mice treated with icariin and icaritin, there was a significant
decrease in the areas positive for CD31 (Yang et al., 2009; Li et al.,
2013b). The anti-angiogenic effect appears to be moderated by
down-regulation of vascular endothelial growth factor (VEGF),
a crucial growth factor that acts as the fundamental regulator of
angiogenesis (Figure 4). The results of both in vitro and in vivo
studies showed a decrease in VEGF levels in both the icaritin-
and icariside-II treated groups (Choi et al., 2008; Li et al., 2013b).
Based on the study reported by Choi et al. (2008), the decreased
level of VEGF is probably due to the reduction in transcriptional
activity of hypoxia inducible factor 1-alpha, the primary regulator
of the expression of VEGF. Taking all of the above into account,
inhibition of VEGF is likely to be the target of icariin and its
derivatives with respect their anti-angiogenic effect.
Inhibition of Metastasis
The malignancy of cancers is mainly due to the ability of
cancer cells to invade their neighboring tissues. This process
of invasion allows neoplastic cells to enter the blood stream
and lymphatic system and reach other organs where secondary
tumors may form. The development of metastases is the cause
of treatment failure and death in cancer patients. The key steps
for metastases are cell attachment, local proteolysis and cell
migration (Harlozinska, 2005). Icariin and its derivatives have
also been investigated with reference to their anti-metastatic
activity. A study on highly metastatic human lung main cancer
cells demonstrated a reduced ability of these cells to invade
and migrate following treatment with icariin (Mao et al.,
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TABLE 2 | Cell cycle modulation of icariin and its derivatives.
Compound Cell Line Study Type Mechanism References
Icariin Human gallbladder carcinoma cells (GBC-SD
and SGC-996)
In vitro G0/G1 phase cell cycle arrest due to inhibition of expression of
survivin
Zhang et al., 2013
Colorectal Cancer Cells (HCT116 and HT29) In vitro G2/M phase cell cycle arrest through suppression of NF-κB
activation and downregulation of Cyclin D1
Zhang et al., 2014
Icaritin Breast cancer cells (MDA-MB-453 and MCF7) In vitro G2/M phase cell cycle arrest accompanied by downregulation of
the expression levels of the G2/M regulatory proteins such as
Cyclin B, cdc2 and cdc25C
Guo et al., 2011
Human prostate carcinoma cells (PC-3) In vitro G1 cell cycle arrest through increased expression of pRb, p27Kip1,
and p16Ink4a as well as decreased expression of phosphorylated
pRb, Cyclin D1 and CDK4.
Huang et al., 2007
Human endometrial cancer cells (Hec1A) In vitro Reductions of cyclin D1 and cdk4 protein expression and
inductions of p21 and p27 expression.
Tong et al., 2011
Extranodal NK/T-cell lymphoma cells (SNK-10
and SNT-8)
In vitro G2/M phase cell cycle arrest through inhibition of Jak/Stat3 and
PI3K/Akt signaling pathway mediated by reduced expression of
LMP1.
Wu et al., 2015b
Human lung cancer cells (A549) In vitro S phase cell cycle arrest through downregulation of expression
levels of S regulatory proteins such as Cyclin A and CDK2
Zheng et al., 2014
Human multiple myeloma cells U266 (ATCC
TIB-196) and Human primary multiple myeloma
cells
In vitro and In
vivo
S phase cell cycle arrest downregulation of expression levels of S
regulatory proteins such as Cyclin A, Cyclin B and CDK2 and
upregulated the expression of Cyclin E
Zhu et al., 2015
Icariside II Human osteosarcoma cells (MG-63 and
Saos-2)
In vitro and In
vivo
Inhibition of epidermal growth factor (EGF)-induced activation of
EGFR/mTOR signaling pathway, including EGFR,
PI3K/AKT/PRAS40, Raf/MEK/ERK as well as mTOR.
Geng et al., 2014
Human eosophageal squamous carcinoma
(Eca109)
In vitro and In
vivo
Downregulation of survivin and Cyclin D1, inhibition of
β-catenin-dependent signaling.
Wang et al., 2011b
Human melanoma cells (A375) In vitro G0/G1 and G2/M phases cell cycle arrest through generation of
ROS and activation of p38 and p53, accompanied by Inhibited the
expression of cell-cycle related proteins, including Cyclin E, CDK2,
Cyclin B1, and P-CDK1
Wu et al., 2015a
TABLE 3 | Anti-angiogenic effect of icariin and its derivatives.
Compound Model/Cell Line Study Type Observation/Mechanism References
Herba Epimedii ethyl
acetate fraction
HUVECS and Zebrafish
embryos
In vitro and
In vivo
Inhibition of HUVECs proliferation, migration, and VEGF-induced tube formation as
well as significant inhibition of blood vessel formation in zebrafish embryos, due to
inhibition of ERK signaling pathways
Yu et al., 2013
Icariin HepG2 tumor In vivo Decrease in CD31+ vessels in tumor Yang et al., 2009
HUVECS and CAM
Assay
In vitro and
In vivo
Inhibition of proliferation of HUVECs and inhibition of angiogenesis in CAM, reduced
expression of VEGF
Ye et al., 2015
Icaritin CAM Assay In vivo Inhibition of angiogenesis in CAM Hong et al., 2013
Renca tumor In vivo Decrease in the mean positive area of CD31 in immunohistochemical analyses of
tumor, reduced expression of VEGF, due to inhibition of activity of STAT3
Li et al., 2013b
HUVECS In vitro Inhibition of HUVEC proliferation, migration and tube formation Zhang, 2014
Icariside II HUVECS In vitro Inhibition of angiogenic function with reduced widths and lengths of the endothelial
network-like structures in HUVECS, reduced expression of VEGF in human
osteosarcoma cells
Choi et al., 2008
2000). In another study, icariin suppressed the adhesion of
lung adenocarcinoma (Di et al., 2015). The possible mode of
action includes effects on vasodilator-stimulated phosphoprotein
(VASP) which is reported to be crucial in cell migration as well
tumor metastasis. VASP function in turn is regulated by Rac, a
member of the Rho family proteins (Schlegel et al., 2000). The
study has also revealed the inhibition of human gastric cancer
cell invasion and cell migration by icariin and the underlying
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FIGURE 4 | Anti-angiogenic effect of icariin and its derivatives. The treatment of icariin, icaritin, and icariside II have resulted in anti-angiogenic effect. This can
be due to the reduction in expression of VEGF, a crucial growth factor that acts as the fundamental regulator of angiogenesis.
mechanism was suggested to be the suppression of expression of
cell motility-related genes Rac1 and VASP (Wang et al., 2010).
Icaritin was also tested on glioblastoma cell line. There
was suppression of adhesion, migration and invasion of
glioblastoma cells, due to downregulation of extracellular matrix
metalloproteinase via PTEN/Akt/HIF-1α pathway (Xu et al.,
2015). Icariside II was also found to exert anti-metastatic
effects as it inhibited the migration of human osteosarcoma
cells by suppressing the transcription of hypoxia-inducible
genes involved in tumor cell invasion, including urokinase
plasminogen activator receptor, adrenomedullin, and matrix
metalloproteinase 2 (Choi et al., 2008). The CXCR4/CXCL12
signaling axis is known to be involved in the metastasis of cancer
cells and CXCR4 chemokine receptors are highly expressed
in various tumors compared to normal cells (Kim and Park,
2014). In a study, the anti-metastatic activity of icariside II
was shown to be correlated with downregulation of CXCR4 at
transcriptional level through the suppression of NF-κB activation
(Kim and Park, 2014). The chronic inflammation that occurs
during cancer treatment is an important factor that induces
tumor metastasis because an inflammatory microenvironment is
favorable for cancer invasion and metastasis through epithelial-
mesenchymal transition (EMT). Studies have been done on the
effect of exposure to icariside II on the migration of non-small
cell lung cancer cells in an inflammatory microenvironment;
the exposure of icariside II resulted in the inhibition of TNF-α-
boosted EMT, migration and invasion of cancer cells, probably
through the inhibition of Akt/ NF-κB pathway. This is supported
by the results of an in vivo study that showed anti-metastastic
effect of icariside II on tumor in nude mice (Song et al., 2016).
The findings of these studies revealed that icariin and
its derivatives inhibit the metastasis of cancer cells through
downregulation of proteins that are crucial for cancer metastasis,
as summarized in Table 4 and Figure 5.
Inhibition of Hormone Dependent Cancers
Breast and prostate cancers are the commonest invasive hormone
dependent cancers in females and males, respectively. Although
these two types of cancers have different physiological features
depending on the organs where they arise, they have common
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TABLE 4 | Anti-metastatic effect of icariin and its derivatives.
Compound Cell Line Study Type Mechanism References
Icariin Human lung adenocarcinoma cells
(A459)
In vitro Decreased migration and adhesion of cells Di et al., 2015
Human lung cancer cells (PG) In vitro Decreased cell adhesive ratio to laminin substrate and reduced
cell ability of invasion or migration
Mao et al., 2000
Gastric carcinoma cells (BGC-823) In vitro Inhibition of cells migration through downregulation of cell
motility-related genes Rac1 and VASP
Wang et al., 2010
Icaritin Human glioblastoma cells (U87MG) In vitro Downregulation of EMMPRIN via the PTEN/Akt/HIF-1α signaling
pathway
Xu et al., 2015
Human osteosarcoma cells (SaOS2) In vitro Decreased cell motility, through downregulation of MMP-2 and
MMP-9 expression
Wang and Wang, 2014
Icariside II Human osteosarcoma cells (HOS) In vitro Inhibition of the transcription of hypoxia-inducible genes involved
in invasion/migration, such as uPAR, ADM, and MMP2
Choi et al., 2008
Human cervical cancer cells (HeLa)
and Breast cancer cells
(MDA-MB-231)
In vitro Downregulation of the expression of CXCR4, through suppression
of NF-κB activation
Kim and Park, 2014
Human non-small cell lung cancer
cells (A549 and H1299)
In vitro and
In vivo
Inhibit of TNF-α-induced migration and EMT of cancer cells in vitro
and in vivo, through inhibition of Akt/NF-κB pathway
Song et al., 2016
FIGURE 5 | Anti-metastatic effect of icariin and its derivatives. Icariin, icaritin, and icariside II inhibit metastasis of tumor by inhibiting cell adhesion, migration,
and invasion through multiple mechanisms that resulted in downregulation of VASP, CXCR4, uPAR, ADM, and matrix metalloproteinases.
pathological features of “hormonal-dependence” (Belev and
Vrbanec, 2013). The initiation and progression of these diseases
are based on the modulation of hormone effects through
specific steroid hormone receptors including estrogen receptors,
progesterone receptors and androgen receptors (Rau et al.,
2005).
Estrogens are known to stimulate the growth of breast
cancer and most breast cancers have overexpression of estrogen
receptor alpha (ERα). It has been found that some ERα –
positive tumors can develop resistance toward hormone therapy.
These indicate a role of ERα in initiation and progression of
cancer (Ali and Coombes, 2000). Icaritin has been reported to
inhibit the estradiol-stimulated growth of ERα-positive breast
cancer cells by destabilizing ERα protein. Icaritin activates the
aryl hydrocarbon (Ahr)-mediated pathways by acting as an
Ahr agonist; resulting in Ahr-mediated proteosomal pathways
Frontiers in Pharmacology | www.frontiersin.org 10 June 2016 | Volume 7 | Article 191
Tan et al. Anticancer Mechanisms of Icariin and Its Derivatives
and degradation of ERα protein which ultimately reduces the
maximal estrogen responsiveness. In an athymic nude mouse
model, icaritin also restricted estradiol-stimulated breast cancer
xenograft growth and caused strong reduction in ERα protein
levels (Tiong et al., 2012). This finding is consistent with another
recent study which showed undetectable levels of ERα protein
in breast cancer tumors of nude mice due to the presence of
icaritin and desmethylicaritin in serum after the administration
of Epimedium bervicornum extract (Indran et al., 2014).
Androgens play a crucial role for survival and growth of
prostatic carcinoma cells; hence, androgen deprivation therapy
has been used as the mainstay of treatment for prostate cancer.
This includes the reduction of gonadal androgen synthesis as well
as disruption of androgen receptor (AR) signaling axis. However,
the mechanism of cancer development has evolved and some
variants have developed into castration-resistant prostate cancer
(CRPC) (Belev and Vrbanec, 2013). This occurs where there
is persistent AR signaling which is postulated to be produced
by AR COOH-terminal truncated splice variants (ARvs) (Sun
et al., 2015a). Recently, icaritin has been tested on CRPC cells
and was found to exert similar effects to those seen in estrogen
responsive breast cancer, with promotion of degradation of AR
and ARvs through the binding of icaritin to Ahr. Consequently,
the transcription of genes regulated by AR and ARvs such
as KLK3 and UBE2C are suppressed, inducing apoptosis of
cancer cells. In an in vivo study, reduction of tumor growth
was seen in murine models implanted with androgen-sensitive
and CRPC cells, due to inhibition of AR signaling by icaritin
(Sun et al., 2015a). In another study, the treatment of androgen
receptor-positive prostate cancer cells with icariside II resulted
in downregulation of expression of KLK3 gene, showing the
role of icariside II in inhibition of AR signaling (Miura et al.,
2015).
Based on the research, icaritin and its derivative are effective
against hormone dependent cancers that are resistant toward
hormone therapy by promoting the degradation of hormone
receptors through Ahr-dependent pathway.
Inhibition of Cancer Stem Cells
Cancer stem cells (CSCs), also known as cancer/tumor-initiating
cells, can be defined as a small population of cancer cells
that are able to self-renew and differentiate into a wide range
of progeny cells that make up the tumor as well as reform
the original tumor following xenotransplantation (Kim et al.,
2009). Although conventional cancer therapy—including radio
and chemotherapy—destroy the bulk of cancer cells, they often
fail to eradicate the critical CSCs due to inherent resistance
mechanisms. Consequently, CSCs form new tumors, which
results in relapse of the cancers (Vinogradov and Wei, 2012).
The inhibitory effect of icaritin on CSCs has been evaluated with
one study reporting more effective inhibition of growth of breast
cancer stem/progenitor cells following treatment with icaritin
compared to the standard chemopreventive agent tamoxifen
(Guo et al., 2011). Recently, the inhibition of malignant growth
of hepatocellular carcinoma initiating cells (HCICs) by icaritin
has been demonstrated (Zhao et al., 2015). The hepatosphere
cells (HCIC that formed spherical clusters) were inhibited from
forming secondary passage of hepatospheres due to the effect of
icaritin which negatively regulated the self-renewal of HCICs. In
addition, the hepatosphere cells lost their ability to initiate tumor.
In in vivo work, growth of primary and secondary xenografts
in NOD/SCID mice were also suppressed. The underlying
mechanism for these observed effects was proposed to be the
attenuation of IL-6 receptors/Jak2/Stat3 signaling (Zhao et al.,
2015). These recent findings show the potential of icaritin in
eradicating CSCs; and seem to suggest that it may be worthwhile
conducting further studies on icariin and its other derivatives to
evaluate their effectiveness against other types of CSCs.
Inhibition of Resistant Cancer Cells
Another huge challenge for anticancer therapy is the emergence
of drug resistance over the course of treatment which has led
to drug-limiting toxicities and failure of chemotherapy (Crespo-
Ortiz and Wei, 2012; Chan et al., 2016). The resistance of cancer
cells can develop via biological mechanisms such as reduced
uptake of drugs, changes in cellular pathways and increased
drug eﬄux. The most common mechanism is overexpression of
ATP-binding cassette (ABC) transporters such as P-glycoprotein
(P-gp) that extrudes the chemotherapeutic agents from the
cells (Liu et al., 2009). In the study by Song et al. (2014),
the combined treatment of Epimedium koreanum Nakai extract
with gefitinib overcame the resistance of non-small cell lung
cancer cells to gefitinib, showing the potential of bioactive
components in Herba epimedii to treat cancers with drug-
resistance. Hence, studies have been carried out to unravel
the reversal of drug resistance of tumor cells by icariin and
its derivatives. One study using multiple drug-resistant (MDR)
human hepatocellular carcinoma/Adriamycin (ADR) cell line
revealed the capability of icaritin to reverse the cytotoxicity of
ADR in a dose-dependent manner, which was due to the decrease
in expression of MDR1 gene, decrease in P-gp level and increased
intracellular accumulation of ADR (Sun et al., 2013). Similar
results were obtained in a study on MDR reversal activities
of a series of semi-synthesized icariin derivatives using ADR-
resistant breast carcinoma cells (Liu et al., 2009). In another
study, the treatment of icariin resulted in the inhibition of
the P-gp-mediated active transport process. In addition, there
was enhanced doxorubicin (DOX)-induced apoptosis in DOX-
resistant human osteosarcoma cells and this was due to the
inhibition of PI3K activity and reduced phosphorylation of
Akt in the cells (Wang et al., 2015b). Recently, icaritin has
been shown to overcome the resistance of human glioblastoma
cells to apoptosis caused by tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL). Treatment with icaritin
has been shown to cause the inhibition of NF-κB signaling
which in turn leads to the suppression of the expression of
cellular PLICE-inhibitory protein (c-FLIP), the inhibitor of
apoptotic signaling. Consequently, TRAIL-induced apoptosis
in glioblastoma cells can be sensitized (Han et al., 2015).
Overall, icariin and its derivatives are able to reverse the drug
resistance of cancer cells, mainly by inhibiting the activity
of P-gp and promoting the accumulation of drug in cancer
cells.
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Immunomodulation
There is increased interest in focusing the application of tumor
immunology for cancer therapy (Ménard et al., 2008). Myeloid-
derived suppressor cells (MDSCs) are part of the myeloid-
cell lineage and they are the heterogenous population of
cells which consist of myeloid-cell progenitors and precursors
of myeloid cells. In healthy individuals, MDSCs quickly
differentiate into mature granulocytes, macrophages, or dendritic
cells (DCs). However, in pathological conditions such as
cancer, differentiation of MDSCs and subsequent expansion
of the cell population is blocked (Gabrilovich and Nagaraj,
2009). As MDSCs possess immunosuppressive functions, their
accumulation is thought to be crucial in protecting the tumor
cells from immune-mediated killing which then facilitates tumor
growth and metastasis, especially in solid cancers. Therefore,
targeting MDSCs could be another approach for cancer therapy
(Marvel and Gabriolovich, 2015). In a study, in vitro treatment of
MDSCs with icaritin led to a reduced proportion of MDSCs with
induction of differentiation of the cells into macrophages and
DCs. There have been in vivo experiments with tumor bearing
mice where treatment with icaritin and icariin has delayed tumor
progression and reduced the percentage of MDSCs. The levels
of arginase, nitric oxide and ROS were determined as they are
involved in MDSC-mediated T-cell suppression and the results
showed significantly lower production of nitric oxide and ROS
as well as restoration of CD8+ T cells functional capacity.
In addition to that, there was downregulation of expression
of S100A8 and S100A9, the pro-inflammatory mediators that
inhibit the differentiation of MDSCs. There was also inhibition
of activation of STAT and AKT (Zhou et al., 2011). Based on
these studies, the immunomodulatory effect of icariin and icaritin
indicates that they are not only effective in killing tumor cells
but they are also involved in antitumor immunity for tumor
regression.
Applications in Medicines
Besides the studies on icariin and its derivatives alone as
potential anticancer agents, there is tremendous interest in
using these compounds in combination with standard anticancer
chemotherapy, as shown in Table 5. This is to enhance the
efficacy of the chemotherapy while reducing the side effects
and complications (Wang et al., 2015c). While treatment
with either icariin or temozolomide resulted in inhibition of
cell proliferation of glioblastoma cells, cell apoptosis and cell
migration inhibition; a combination of icariin and temozolomide
led to significant enhancement of these antitumor activities
compared to the treatment using either agent alone. The
synergistic effect was correlated with the suppression of NF-κB
activity (Yang et al., 2015). This is consistent with synergistic
effects that were observed in other in vitro and in vivo
studies using different anticancer drugs such as gemcitabine,
5-florouracil and arsenic trioxide. Other than inhibition of
NF-κB activity, an increase in the generation of intracellular
ROS was observed (Zhang et al., 2013; Li et al., 2014a; Shi
et al., 2014; Wang et al., 2015c). Recently, the effect of icaritin
used in combination with epirubicin against bladder cancer
cells was investigated. The results showed that icaritin acted
synergistically with epirubicin via suppression of autophagy (Pan
et al., 2016). For extranodal NK/T-cell lymphoma cells, icaritin
potentiated ganciclovir-induced apoptosis through induction of
lytic Epstein–Barr virus infection (Wu et al., 2015b). With
reference to studies on icariside II, a synergistic effect was also
observed in different cell lines when it was used in combination
with drugs such as bortezomib, thalidomide and paclitaxel. There
was an increase in the expression of cleaved caspase 3, showing
that icariside II potentiated the apoptosis of cancer cells induced
by these chemotherapeutic agents with the possible mechanisms
involved being inhibition of STAT3 signaling pathways as well as
TLR4-MyD88-ERK signaling (Kim et al., 2011; Wu et al., 2012).
Other than chemotherapy, ionizing radiation (IR) therapy is
also used as a main treatment of many types of malignancies.
However, there are some drawbacks of IR therapy such as
treatment-induced resistance, epidermitis and higher risk of
cardiovascular disease. Hence, there is a need for an agent or
radiosensitizer that can overcome radioresistance and sensitize
the malignant cells to radiation. This will also help to enhance the
tumor response facilitating the use of lower therapeutic doses of
radiation which will help reduce toxicity to other organs (Hong
et al., 2013; Zhang et al., 2014). The synergistic effect of icaritin
with IR has been demonstrated (Hong et al., 2013) through three
main pathways. Firstly, icaritin blocks the activation of survival
signaling such as ERK1/2 and AKT pathways of breast cancer
cells that are caused by IR stress. Secondly, icaritin enhances
the accumulation of cells in G2/M phase, causing more cells to
die. Thirdly, the induction of necrosis and apoptosis of cancer
cells by icaritin occurs in a dose-dependent manner, preventing
the IR-insulted cells from repairing the damage. Similar results
were obtained in a study that used icariin as a radiosensitizer
of colorectal cancer cells (Zhang et al., 2014). One of the
possible underlying mechanisms for these observed effects is the
suppression of NF-κB activity by icaritin, which then prevents the
activation of pro-proliferative genes such as ERK1/2 and AKT
as well as causing cell cycle arrest in G2/M phase. Based on the
reported studies, co-treatment using icariin and its derivatives
in combination with standard cancer therapies results in positive
effects because they potentiate apoptosis of cancer cells induced
by chemotherapy through their action on different signaling
pathways. In addition to that, they also help to overcome the
radioresistance of cancer cells.
There are a number of patents registered related to the
application of icariin and its derivatives in cancer treatment.
For example, icariin has been used to treat melanoma and
breast cancers (Dong et al., 2011). Icaritin has been utilized in
the preparation of medicaments for primary liver cancer and
inhibition of liver cancer stem cells (Meng et al., 2014, 2015);
while Zhang and Calderwood (2008) reported the application of
desmethylicaritin as the active ingredient of an antitumor drug.
Broad-spectrum antitumor effects have been shown and it is
found to be maintained at a particular concentration in plasma,
which is a desirable property for antitumor effect. Icaritin has
also been used together with juglanin B for the treatment of
hepatocellular carcinoma (Zhao et al., 2014). Other derivatives
such as icariinaglycon and cyclo-icariin have also been utilized
in treatment of different cancer cell lines (Wang et al., 2011c; Jia
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TABLE 5 | Applications of icariin and its derivatives with current cancer therapy.
Compound Cell Line Study Type Drug/Treatment Effect References
Icariin Human Hepatocellular Carcinoma
(SMMC-7721 and HepG2)
In vitro and
In vivo
Arsenic trioxide Potentiates antitumor effect of arsenic trioxide through
by generation of intracellular ROS and inhibition of NF-κB
activity
Li et al., 2014a
Human colorectal carcinoma cells
(HT29 and HCT116)
In vitro and
In vivo
5-fluorouracil Potentiates antitumor effect of 5-fluorouracil through
inhibition of NF-κB activity
Shi et al., 2014
Human myeloid leukemia cells (HL-60
and NB4)
In vitro Arsenic trioxide Potentiates antitumor effect of arsenic trioxide through
generation of intracellular ROS
Wang et al., 2015c
Human glioblastoma cells (U87MG) In vitro Temolozomide Potentiates antitumor effect of temolozomide through
inhibition of NF-κB activity
Yang et al., 2015
Human gallbladder carcinoma cells
(GBC-SD and SGC-996)
In vitro and
In vivo
Gemcitabine Potentiates antitumor effect of gemcitabine through
inhibition of NF-κB activity and downregulation of NF-κB
-regulated gene products
Zhang et al., 2013
Colorectal Cancer Cells (HCT116 and
HT29)
In vitro and
In vivo
X-ray irradiation Potentiate radiation-induced apoptosis of cancer cells
through suppression of radiation-induced NF-κB
activation and downregulation of NF-κB -regulated gene
products
Zhang et al., 2014
Icaritin Murine breast cancer cells (4T1) In vitro Ionizing radiation Potentiate radiation-induced apoptosis and inhibition of
cell proliferation as well as suppression of IR-induced
survival path, ERK1/2 and AKT
Hong et al., 2013
Bladder cancer cells (BT5637 and
T24)
In vitro Epirubicin Inhibition of epirubicin-induced autophagy and
synergistic effect with epirubicin to suppress cancer cell
proliferation
Pan et al., 2016
Extranodal NK/T-cell lymphoma cells
(SNK-10 and SNT-8)
In vitro Ganciclovir Potentiates ganciclovir-induced apoptosis through
induction of lytic EBV infection
Wu et al., 2015b
Icariside II Multiple myeloma cells (U266) In vitro Bortezomib and
Thalidomide
Enhanced cytotoxicity of bortezomib and thalidomide
through enhancement of apoptosis
Kim et al., 2011
Human melanoma cells (A375) In vitro Paclitaxel Potentiates paclitaxel-induced apoptosis through
inhibition of paclitaxel activated TLR4–MyD88–ERK
signaling
Wu et al., 2012
et al., 2014). The preparations of icariin and its derivatives for
cancer treatment appear to be advantageous because they show
low toxicity to normal cells and no obvious adverse effects (Meng
et al., 2014; Wei et al., 2015).
Comparison of Potency of Icariin
Derivatives and Challenges in Clinical
Usage
In a comparative study done by Huang et al. (2007), icariin
and icaritin exert anticancer effect against PC-3 cells to different
extents. Icaritin had a stronger effect on PC-3 cells by causing
G1 and G2/M arrest whereas icariin only caused weak G1 arrest.
The different level of potency of the two compounds in inhibiting
cell growth could be due to the difference in their chemical
structures. The possible structure-activity relationship was
further demonstrated by another study with icariin and icaritin.
Although both icariin and icaritin exerted immunomodulatory
and antitumor effects, icariin showed weaker action as it did not
affect the proportion of MDSCs, macrophages and DCs in vitro
and furthermore, had no effect on the expression of S100A8/9 in
MDSCs in vitro (Zhou et al., 2011).
Pharmacological studies have clearly shown that icariin,
icaritin and icariside II possess anticancer activity but the
challenge for their experimental studies is the small amount
of natural icaritin and icariside II present in Herba Epimedii.
In order to increase the yield of icaritin and icariside II
from icariin, enzyme hydrolysis methods have been used to
prepare higher amounts of these metabolites for pharmacological
studies (Xia et al., 2010; Jin et al., 2012). Another impediment
to the clinical application of icariin, icaritin and icariside II
is their low solubility in water which will lead to low in
vivo bioavailability (Cai et al., 2011; Wang et al., 2015a).
In order to enhance their water solubility, other derivatives
have also been synthesized. For example, Wang et al. (2015a)
prepared a series of icaritin derivatives bearing carboxylic
acid or carboxylic ester groups and their enhanced cytotoxic
activity against breast and lung cancer cells was demonstrated.
Song et al. (2015) demonstrated another approach for the
enhancement of solubility, which is by incorporating icariside
II into phospholipid/d-α-tocopheryl polyetheyene glycol 1000
succinate (TPGS) mixed micelles. The mixed micelles loaded
with icariside II showed stronger inhibition action on the
proliferation of breast cancer cells compared to icariside II alone.
Similar effects were observed in lung cancer cells treated with
lecithin/Solutol HS 15 loaded with icariside II (Yan et al., 2015).
These results demonstrate that icariin and its derivatives have
real potential given that one of the main potential limitations of
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FIGURE 6 | Anti-cancer mechanisms of icariin and its derivatives. Icariin and its derivatives mainly inhibit the growth of tumor through induction of apoptosis by
targeting multiple signaling pathways. Cell cycle arrests also occur through downregulation of the expression of cell cycle regulatory proteins. Besides, there are
anti-angiogenesis, anti-metastasis and immunomodulation. The compounds are also effective in targeting hormone-dependent cancers, cancer stem cells, and
drug-resistant cancer cells. There are synergistic effects when icariin and its derivatives are used together with standard cancer therapy such as chemotherapy or
radiotherapy.
low solubility can be overcome via the application of novel drug
delivery systems.
CONCLUSION
Overall, the existing research provides supporting scientific-
based evidence that substantiates the use of Herba Epimedii-
containing herbal medicine for anticancer treatment. The active
compound in Herba Epimedii, icariin and its derivatives possess
tremendous potential for treatment of many different cancers—
including solid and non-solid tumors. They were found to act
through a wide variety of mechanisms as shown in Figure 6.
The tantalizing promise of these compounds as suggested by
the current work is the ability of these substances to overcome
the limitations of current anticancer therapy—including the
ability to effectively kill cancer stem cells and help overcome
hormone therapy resistance in hormone dependent cancers.
Their anticancer activity which goes beyond cytotoxicity to
include more novel mechanisms such as immunotherapy is also
a fascinating aspect which begs further study. Given that icariin
and its various derivatives seem to have different levels of potency
with reference to their anticancer effects, work remains to be
done to identify the ones with the strongest anticancer activity;
this is at the moment challenging as the full details of their
mechanisms of action are still not known and the amount of
comparative studies at present are limited. The safety profile
of these compounds appears promising as clinical trials and a
patents study suggest that they can safely be used without adverse
effects. All in all, icariin and its derivatives have tremendous
potential as candidates for research in the development of new
anti-cancer agents.
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